Vigabatrin for Treatment of Cocaine Dependence

Phase 2

Completed

Brief Summary: The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.

Detailed Description: Cocaine addiction, a serious public health concern associated with significant medical, social, and economic consequences, is difficult to treat using traditional psychosocial and behavioral therapies. Despite testing of a number of different agents for cocaine dependency, there remains no proven pharmacologic treatment for cocaine addiction.

The addictive properties of cocaine have been associated with its actions on mesotelencephalic dopamine reward pathways in the central nervous system (CNS). Cocaine administration increases the levels of dopamine, a neurotransmitter associated with sensations of pleasure and reward. Therefore, blocking cocaine-induced increases in dopamine levels represents a valid pharmaceutical approach to the treatment of cocaine addiction.

Another neurotransmitter, gamma-aminobutyric acid (GABA), suppresses striatal dopamine release, and attenuates cocaine-induced increases in extracellular and synaptic dopamine levels in the striatum and nucleus accumbens in animal models of drug dependence. Significant elevation of brain GABA levels may reduce cocaine-stimulated dopamine release and dampen the sensations of pleasure and reward. Thus, drugs that potentiate or enhance GABA-ergic transmission are candidates for the treatment of cocaine addiction.

Recruitment & Eligibility

Inclusion Criteria

Able to understand the study and provide written informed consent.
Male or female at least 18 years of age.
Meets DSM-IV (Diagnostic and Statistical Manual of Mental Disorders Fourth Edition) criteria for cocaine dependence as primary diagnosis, as determined by the Substance Abuse module of SCID (Structured Clinical Interview for DSM-IV).
Provide at least one urine sample that is positive for cocaine according to a rapid screening test.
Seeking treatment for cocaine dependence.
Have normal visual fields.
Be in generally good health based on history, physical examination, electrocardiogram and laboratory findings.
If female of childbearing potential, use acceptable contraceptive methods. (oral contraceptives (the pill), IUDs, contraceptive implants under the skin, contraceptive rings or patches or injections, diaphragms with spermicide, and condoms with spermicide). Surgical sterilization by tubal ligation or hysterectomy is acceptable

Exclusion Criteria

Has current dependence, as determined by the SCID, on any psychoactive substance other than cocaine, alcohol, nicotine, or marijuana or physiologic dependence on alcohol requiring medical detoxification.
Has any serious medical or psychiatric illness and/or clinically significant abnormal laboratory value, which in the judgment of the Principal Investigator or his/her designee would make study participation unsafe, or would make treatment compliance difficult or put the study staff at undue risk.
Be under court mandate to obtain treatment.
Be enrolled in an opiate substitution treatment program within 2 months of randomization.
Has ever taken vigabatrin in the past.
Is pregnant or lactating.
Has clinically significant ophthalmologic disease, which would preclude safety monitoring or is undergoing treatment for ocular disease.
Has received a drug with known major organ toxicity, including retinotoxicity within 30 days of randomization.
Is currently participating in, or has been enrolled in another clinical trial within the last 30 days.
Be anyone who, in the judgment of the investigator, would not be expected to attend regular study visits or to complete the study protocol, due to imminent relocation from the clinic area, legal difficulties, work-related problems, transportation, etc.

Arm && Interventions

Group	Intervention	Description
2	placebo	3 Placebo Tablets, bid, for 9 weeks
1	vigabatrin	3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks

Primary Outcome Measures

Name	Time	Method
Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment.	Week 13	Number of subjects in the CPP-109 Vigabatrin Group vs. Number in Placebo Group abstinent from using cocaine during Weeks 11 and 12 of the Treatment Phase.

Secondary Outcome Measures

Name	Time	Method

Locations (11): Johns Hopkins Bayview Medical Center Center for Chemical Dependence
🇺🇸
Baltimore, Maryland, United States
Addiction Treatment Clinic
🇺🇸
Little Rock, Arkansas, United States
Friends Research Institute
🇺🇸
Torrance, California, United States
St. Luke's Hospital Addiction Pharmacology Research Laboratory
🇺🇸
San Francisco, California, United States
Operation PAR
🇺🇸
Largo, Florida, United States
Segal Institute for Clinical Research
🇺🇸
North Miami, Florida, United States
Dayton Veterans Affairs Medical Center
🇺🇸
Dayton, Ohio, United States
New York University Mental Health and Addictive Disorders Research Program
🇺🇸
New York, New York, United States
University of Texas Health Science Center at San Antonio
🇺🇸
San Antonio, Texas, United States
Cincinnati Addiction Research Center (CinARC)
🇺🇸
Cincinnati, Ohio, United States
Boston University School of Medicine
🇺🇸
Boston, Massachusetts, United States